Valuation: Dianthus Therapeutics, Inc.

Market Cap 5.07B 4.45B 4.2B 3.83B 7.17B 486B 7.22B 50.32B 19.49B 248B 19.05B 18.64B 798B P/E 2026 *
-23.6x
P/E 2027 * -19.2x
Enterprise Value 5.22B 4.58B 4.32B 3.94B 7.37B 500B 7.43B 51.72B 20.03B 255B 19.58B 19.16B 821B EV / Sales 2026 *
2,806x
EV / Sales 2027 * 2,864x
Free-Float
99.88%
Yield 2026 *
-
Yield 2027 * -
1 day-4.09%
1 week-7.59%
Current month-11.52%
1 month-15.11%
3 months+2.91%
6 months+18.96%
Current year+126.74%
1 week 89.78
Extreme 89.78
100.47
1 month 89.78
Extreme 89.78
112.13
Current year 35.84
Extreme 35.84
117.88
1 year 32.22
Extreme 32.22
117.88
3 years 6.58
Extreme 6.58
117.88
5 years 6.58
Extreme 6.58
117.88
10 years 6.58
Extreme 6.58
117.88
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-10
Director of Finance/CFO 37 2023-09-10
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 58 2023-09-10
Director/Board Member 50 2023-09-10
Chairman 64 2023-09-10
Date Insider Type Main position Quantity % Market Cap. Importance
9/17/26 Exercice

Controller/Auditor

60,000 0.1864%
9/1/26 Exercice

Chief Technology Officer

69,372 0.2155%
8/19/26 Exercice

Director

8,334 0.0149%
Change 5-day change 1-year change 3-year change Capi.($)
-4.09%-7.59%+151.25%+597.31% 5.07B
-3.30%+1.19%+54.62%+104.15% 71.94B
+1.25%-3.01%+40.12%+77.12% 59.35B
+2.12%+5.79%+32.63%+24.27% 27.16B
-3.63%-2.42%-13.64%+354.19% 26.54B
+0.36%+3.26%+1.13%-3.81% 24.93B
+0.40%+0.75%+22.91%-9.68% 20.61B
-1.70%-3.35%+146.86%+325.69% 15.03B
+0.21%+1.21%-6.26%+493.02% 14.2B
+0.28%-0.48%+50.12%+166.06% 14.36B
Average -0.81%-0.86%+47.97%+212.83% 27.92B
Weighted average by Cap. -0.80%-0.38%+39.19%+140.21%

Financials

2026 *2027 *
Net sales 1.86M 1.63M 1.54M 1.4M 2.63M 178M 2.65M 18.44M 7.14M 91.02M 6.98M 6.83M 293M 1.78M 1.56M 1.47M 1.34M 2.51M 170M 2.53M 17.63M 6.83M 87.06M 6.68M 6.53M 280M
Net income -206M -181M -171M -156M -291M -19.75B -293M -2.04B -792M -10.09B -774M -757M -32.43B -270M -237M -223M -204M -381M -25.83B -384M -2.67B -1.04B -13.2B -1.01B -990M -42.42B
Net Debt 141M 124M 117M 107M 200M 13.54B 201M 1.4B 543M 6.92B 531M 519M 22.24B 18.85M 16.54M 15.62M 14.24M 26.65M 1.81B 26.84M 187M 72.41M 923M 70.77M 69.24M 2.97B
Logo Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for the treatment of severe autoimmune diseases. The Company's lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (C1s) - enabling less frequent and convenient self-administered subcutaneous (S.C.) injections suitable for a pre-filled pen. It is conducting three mid- to late-stage clinical trials with claseprubart in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN). The Company's second clinical-stage candidate, DNTH212, is an investigational, extended half-life bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Employees
92
Date Price Change Volume
26-09-22 US$93.44 -4.99% 1,187,392
26-09-24 US$90.71 -2.92% 726,361
26-09-23 US$93.44 -4.99% 1,187,399
26-09-22 US$98.35 +1.95% 1,126,842
26-09-21 US$96.47 -0.35% 933,209
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
90.71USD
Average target price
140.80USD
Spread / Average Target
+55.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DNTH Stock